Shenzhen Hepalink Pharmaceutical Group (09989) announced its annual performance with a net profit attributable to shareholders of 349 million yuan, a decrease of 45.96% year-on-year.

Shenzhen Hepalink Pharmaceutical Group (09989) released its performance for the year 2025, with revenue of 5.438 billion yuan (RMB, the same below), a year-on-year increase of 3.41%; the net profit attributable to owners of the parent company was 349 million yuan, a decrease of 45.96% year-on-year; basic earnings per share were 0.24 yuan, and the proposed final cash dividend was 1.45 yuan per ten shares of the company's common stock (including tax). The announcement stated that the increase in revenue from sales of products was mainly due to a significant increase in sales volume of pharmaceutical formulations during the reporting period. The decrease in gross profit margin was mainly due to sales costs including provision for inventory impairment, which increased from 7.6 million yuan in the previous year to 36.5 million yuan, and was also affected by market conditions, with raw material drug prices trending downward.